GSK and Sanofi have reported positive efficacy data from a co-developed vaccine targeting the Omicron variant of Covid-19. The report makes GSK and Sanofi the first companies to have a vaccine candidate for the Omicron variant which has demonstrated efficacy. Specifically, the companies’ B.1.351 vaccine candidate demonstrated 64.7% efficacy in symptomatic Covid-19 adults and 72% […]
